SIOC 中文
CJOG
Adv search

Chinese Journal of Organic Chemistry >

2020 , Vol. 40 >Issue 2: 391 - 397

DOI: https://doi.org/10.6023/cjoc201907006

Design, Synthesis and Biological Activity of Pyrazolo[3,4-d]pyrimidine Derivatives Containing Indole Moiety

  • Sun Xiaoyang ,
  • Feng Siran ,
  • Dong Jinjiao ,
  • Feng Jiajia ,
  • Liu Zhenming ,
  • Song Yali ,
  • Qiao Xiaoqiang
Expand
  • a Key Laboratory of Pharmaceutical Quality Control of Hebei Province, College of Pharmacetical Sciences, Hebei University, Baoding, Hebei 071000;
    b National Drug Clinical Trial Institution, Cangzhou Central Hospital, Cangzhou, Hebei 061000;
    c Drug Design Center, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191;
    d Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Hebei University, Baoding, Hebei 071000

Received date: 2019-07-03

  Revised date: 2019-09-11

  Online published: 2019-11-01

Supported by

Project supported by the Natural Science Foundation of Hebei Province (No. B2018201269), the Research Award Fund Scientific and Technological in Higher Education Institutions of Hebei Province (No. ZD2019060), the National Natural Science Foundation of China (No. 21675039), and the Young Talent of Hebei Province.

Fold

Abstract

Based on the combination principle in drug design, thirteen pyrazolo[3,4-d]pyrimidine derivatives containing indole moiety were designed and synthesized. The target compounds were confirmed by 1H NMR, 13C NMR and HRMS. Their in vitro cytotoxicity against four human cancer cell lines (HeLa、MGC-803、MCF-7、BEL-7404) has been investigated and most of the tested compounds displayed moderate antiproliferative activity. Especially, compound 5m exhibited the highest level of antiproliferative activity with an IC50 value <30 μmol·L-1 for HeLa, MGC-803 and MCF-7. IC50 value of methyl 3-((4-oxo-1-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)thio)-1H-indole-6-carboxylate (5m) to MCF-7 was (4.02±0.92) μmol·L-1, which was better than etoposide (10.1±0.62 μmol·L-1) and camptothecin (5.93±0.56 μmol·L-1). Further biological evaluation of these compounds suggested that these compounds showed selective inhibitory activity against Topo II as a possible intracellular target, and all compounds didn't show inhibitory activity against Topo I.

Key words： indole; pyrazolo[3,4-d]pyrimidine; anticancer; topoisomerase; molecular docking

Cite this article

Sun Xiaoyang , Feng Siran , Dong Jinjiao , Feng Jiajia , Liu Zhenming , Song Yali , Qiao Xiaoqiang . Design, Synthesis and Biological Activity of Pyrazolo[3,4-d]pyrimidine Derivatives Containing Indole Moiety[J]. Chinese Journal of Organic Chemistry, 2020 , 40(2) : 391 -397 . DOI: 10.6023/cjoc201907006

References

[1] Kumar, A.; Ahmad, I.; Chhikara, B. S. Bioorg. Med. Chem. Lett. 2011, 21, 1342.
[2] Piotrowska, D. G.; Cieślak, M.; Królewskan, K. Eur. J. Med. Chem. 2011, 46, 1382.
[3] Hassan, G. S.; Kadry, H. H. Bioorg. Med. Chem. 2011, 19, 6808.
[4] Amir, M.; Javed, S.; Kumar, H. Indian J. Pharm. Sci. 2007, 69, 337.
[5] Bakavoli, M.; Bagherzadeh, G.; Vaseghifar, M.; Shiri, A.; Pordel, M.; Mashreghi, M.; Pordeli, P. Eur. J. Med. Chem. 2010, 45, 647.
[6] Ali, A.; Taylor, G. E.; Ellsworth, K.; Harris, G.; Painter, R.; Lynn, L.; Young K. J. Med. Chem. 2003, 46, 1824.
[7] Raffa, D.; Maggio, B.; Plescia, F.; Cascioferro, S.; Raimondi, M. V.; Plescia, S.; Cusimano, M. G. Arch. Pharm. 2009, 42, 321.
[8] El-Bendary, E. R.; Badria, F. A. Arch. Pharm. 2000, 333, 99.
[9] Chern, J. H.; Shia, K. S.; Hsu, T. A.; Tai, C. L.; Lee, C. C.; Lee, Y. C. Bioorg. Med. Chem. Lett. 2004, 14, 2519.
[10] Guccione, S.; Modica, M.; Longmore, J.; Shaw, D.; Barretta, G. U. Bioorg. Med. Chem. Lett. 1996, 6, 59.
[11] Xia, Y.; Chackalamannil, S.; Czarniecki, M.; Tsai, H.; Vaccaro, H. J. Med. Chem. 1997, 40, 4372.
[12] Angelucci, A.; Schenone, S.; Gravina, G. L.; Muzi, P.; Festuccia, C. Eur. J. Cancer. 2006, 42, 2838.
[13] Manetti, F.; Santucci, A.; Locatelli, G. A.; Maga, G.; Spreafico, A.; J. Med. Chem. 2007, 50, 5579.
[14] Spreafico, A.; Schenone, S.; Serchi, T.; Orlandini, M. Angelucci. A. FASEB J. 2008, 22, 1560.
[15] Celano, M.; Schenone, S.; Cosco, D.; Navarra, M.; Puxeddu, E.; Racanicchi, L. Endocr. Relat. Cancer. 2008, 15, 499.
[16] Ismail, N.; Ali, E.; Ibrahim, D.; Serya, R. Future J. Pharm. Sci. 2016, 2, 20.
[17] Chauhan, M., Kumar, R. Eur. J. Med. Chem. 2013, 21, 5657
[18] Humphrey, G. R.; Kuethe, J. T. Chem. Rev. 2006, 106, 2875.
[19] Horton, D. A.; Bourne, G. T.; Smythe, M. L. Chem. Rev. 2003, 103, 893.
[20] Sharma, V.; Kumar, P.; Pathak, D. J. Heterocycl. Chem. 2010, 47, 491.
[21] Sravanthi, T. V.; Manju, S. L. Eur. J. Pharm. Sci. 2016, 91, 1.
[22] Han, X.-Y.; Li, S.-B.; Liang, G.-C.; Song, Y.-L. Acta Pharm. Sin. 2017, 52, 113(in Chinese). (韩晓燕, 李生彬, 梁国超, 宋亚丽, 药学学报, 2017, 52, 113.)
[23] Li, J.-F.; Zhu, Y.-Q.; Wang, X. J. Heterocycl. Chem. 2007, 44749.
[24] Heravi, M. M.; Nami, N.; Seifi, N. Phosphorus Sulfur 2006, 181, 591.
[25] Reeves, W. P.; Rudis, J. A. Synth. Commun. 1981, 11, 781.
[26] Schenone, S.; Bruno, O.; Ranise, A. Bioorg. Med. Chem. Lett. 2004, 14, 2511.
[27] Fabrizio, M.; Annalisa, S. J. Med. Chem. 2007, 50, 5579.
[28] Zhang, H.; Bao, X.; Song, Y. Tetrahedron 2015, 71, 8885.
[29] Han, X.-Y. M.S. Thesis, Hebei University, Baoding, 2017(in Chinese). (韩晓燕, 硕士论文, 河北大学, 保定, 2017.)
[30] Mosmann, T. J. Immunol. Methods 1983, 65, 55.
Options
Outlines

/

〈 〉